Peter Loftus

Contributor and Reporter, Wall Street Journal, Dow Jones Newswires

About

Wall Street Journal @WSJ reporter covering pharmaceutical industry. Contact me at 215-982-5581, peter.loftus@wsj.com.

Twitter Feed

6,424
followers
1,173
tweets
RT @jonathanrockoff: $88.1bn in healthcare M&A announced this wk & $153.5bn YTD, most since recordkeeping began in 1980--Thomson Reuters' @…
Eli Lilly says Takeda may not cover Lilly's share of $9 billion in damages from Actos lawsuit on.wsj.com/1ibXUaF $LLY
Eli Lilly CEO Lechleiter paints picture of $LLY's M&A/license activity: 'Like a duck floating on water, the feet are paddling away'
Zimmer to buy rival orthopedic device maker Biomet for $13.35 billion. $ZMH on.wsj.com/1jFDNhx
In other drug news... Eleven charged in drug ring on Philadelphia's Main Line. on.wsj.com/1mt06Lc by new WSJ colleague @scottmcalvert
Drug-deal flurry shows companies' swing toward narrower focus on markets like cancer, vaccines. on.wsj.com/1jxPfM7
Gilead hopes to avoid what happened to Vertex--big HepC drug launch then dropoff as patients wait for next generation. $GILD has next gen.
For comparison, AbbVie's Humira, on market since '02, had 4Q13 sales of $3B. Gilead's Sovaldi in 1st full qtr on market: $2.3B $ABBV $GILD
Gilead says 30,000 hepatitis C patients have started therapy on Sovaldi. $GILD
More Statuses

Have a Story?

Send Pitch

Are You a Journalist?

Make a Portfolio
Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Peter Loftus, email loftus@muckrack.com.

Share This Profile